Correction to In Vivo Imaging of Human Neuroinflammation

We recently noticed a typo in our 2016 article, “In Vivo Imaging of Human Neuroinflammation” published in ACS Chemical Neuroscience. In the original version, the language on page 474 reads: Selective MAO-B antagonists have been radiolabeled for PET imaging of astrocytes, including [C]-D-deprenyl and its deuterium substituted analogue, [C]-deprenyl-D2. [C]deprenyl-D2 is the most commonly used astrocyte tracer, because of its favorable kinetics compared to [C]deprenyl. However, specific binding of the molecule has been questioned. The first “[C]-D-deprenyl” should have been “[C]-Ldeprenyl”. We also add a statement about [C]-D-deprenyl. The corrected language is as follows: Selective MAO-B antagonists have been radiolabeled for PET imaging of astrocytes, including [C]-L-deprenyl and its deuterium substituted analogue, [C]-L-deprenyl-D2. [C]-L-deprenyl-D2 is the most commonly used astrocyte tracer, because of its favorable kinetics compared to [C]-Ldeprenyl. The mirror enantiomer of L-deprenyl, D-deprenyl, has also been radiolabeled for use as an astrocytic marker. However, reduced affinity for MAO-B and questionable specific binding of the molecule limit the practicality of using Ddeprenyl as an astrocytic marker. Correction